Cyxone AB Crystalline Rabeximod Oral Formulation
Summary
The European Patent Office published patent application EP4164616A1 filed by Cyxone AB for an oral formulation comprising a crystalline form of the drug compound Rabeximod (EP4164616A1, published April 15, 2026). The application covers a solid oral dosage form containing the crystalline polymorphic form of Rabeximod, classified under IPC codes including A61K 9/48 (oral capsules), A61K 31/4985, and C07D 487/04. The filing is designated across all EPO member states including DE, FR, GB, IT, NL, ES, and 23 others.
About this source
GovPing monitors EPO Patent Bulletin - Organic Chemistry (C07D) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 63 changes logged to date.
What changed
The EPO published patent application EP4164616A1 for Cyxone AB covering an oral pharmaceutical formulation of crystalline Rabeximod. Rabeximod is an immunomodulatory compound being developed for autoimmune and inflammatory conditions including rheumatoid arthritis (A61P 19/02) and immune-mediated diseases (A61P 37/02). The application specifies the crystalline polymorphic form and solid oral dosage form (A61K 9/20/48).
Pharmaceutical companies developing oral formulations of immunomodulatory compounds should review this publication for freedom-to-operate considerations. IP professionals tracking autoimmune and rheumatology drug development may use this as a competitive landscape indicator. The patent's scope and any claims should be reviewed upon grant or during opposition periods.
Archived snapshot
Apr 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ORAL FORMULATION COMPRISING A CRYSTALLINE FORM OF RABEXIMOD
Publication EP4164616A1 Kind: A1 Apr 15, 2026
Applicants
Cyxone AB
Inventors
BJÖRKLUND, Ulf
IPC Classifications
A61K 9/48 20060101AFI20251013BHEP A61K 9/20 20060101ALI20251013BHEP A61K 31/4985 20060101ALI20251013BHEP A61K 31/519 20060101ALI20251013BHEP A61P 19/02 20060101ALI20251013BHEP A61P 29/00 20060101ALI20251013BHEP A61P 37/02 20060101ALI20251013BHEP C07D 487/04 20060101ALN20251013BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.